AU2009313560B2 - Combinatorial antibody libraries and uses thereof - Google Patents

Combinatorial antibody libraries and uses thereof Download PDF

Info

Publication number
AU2009313560B2
AU2009313560B2 AU2009313560A AU2009313560A AU2009313560B2 AU 2009313560 B2 AU2009313560 B2 AU 2009313560B2 AU 2009313560 A AU2009313560 A AU 2009313560A AU 2009313560 A AU2009313560 A AU 2009313560A AU 2009313560 B2 AU2009313560 B2 AU 2009313560B2
Authority
AU
Australia
Prior art keywords
antibody
germline
chain
antigen
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009313560A
Other languages
English (en)
Other versions
AU2009313560A1 (en
Inventor
Omar Bazirgan
Tyson Chase
James Graziano
Helen Hongyuan Mao
Vaughn Smider
Byeong Doo Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fabrus Inc
Original Assignee
Fabrus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabrus Inc filed Critical Fabrus Inc
Publication of AU2009313560A1 publication Critical patent/AU2009313560A1/en
Application granted granted Critical
Publication of AU2009313560B2 publication Critical patent/AU2009313560B2/en
Priority to AU2016204719A priority Critical patent/AU2016204719A1/en
Priority to AU2018201622A priority patent/AU2018201622A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Structural Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
AU2009313560A 2008-11-07 2009-11-04 Combinatorial antibody libraries and uses thereof Ceased AU2009313560B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016204719A AU2016204719A1 (en) 2008-11-07 2016-07-07 Combinatorial antibody libraries and uses thereof
AU2018201622A AU2018201622A1 (en) 2008-11-07 2018-03-06 Combinatorial antibody libraries and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19876408P 2008-11-07 2008-11-07
US61/198,764 2008-11-07
US21120409P 2009-03-25 2009-03-25
US61/211,204 2009-03-25
PCT/US2009/063299 WO2010054007A1 (en) 2008-11-07 2009-11-04 Combinatorial antibody libraries and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016204719A Division AU2016204719A1 (en) 2008-11-07 2016-07-07 Combinatorial antibody libraries and uses thereof

Publications (2)

Publication Number Publication Date
AU2009313560A1 AU2009313560A1 (en) 2010-05-14
AU2009313560B2 true AU2009313560B2 (en) 2016-04-14

Family

ID=41508157

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2009313560A Ceased AU2009313560B2 (en) 2008-11-07 2009-11-04 Combinatorial antibody libraries and uses thereof
AU2009313551A Ceased AU2009313551B2 (en) 2008-11-07 2009-11-04 Anti-DLL4 antibodies and uses thereof
AU2016204719A Abandoned AU2016204719A1 (en) 2008-11-07 2016-07-07 Combinatorial antibody libraries and uses thereof
AU2018201622A Abandoned AU2018201622A1 (en) 2008-11-07 2018-03-06 Combinatorial antibody libraries and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2009313551A Ceased AU2009313551B2 (en) 2008-11-07 2009-11-04 Anti-DLL4 antibodies and uses thereof
AU2016204719A Abandoned AU2016204719A1 (en) 2008-11-07 2016-07-07 Combinatorial antibody libraries and uses thereof
AU2018201622A Abandoned AU2018201622A1 (en) 2008-11-07 2018-03-06 Combinatorial antibody libraries and uses thereof

Country Status (7)

Country Link
US (4) US9221902B2 (enExample)
EP (2) EP2356270B1 (enExample)
JP (4) JP5882058B2 (enExample)
AU (4) AU2009313560B2 (enExample)
CA (2) CA2742968C (enExample)
DK (1) DK2356270T3 (enExample)
WO (2) WO2010054010A1 (enExample)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US8420779B2 (en) 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
KR20100126811A (ko) 2008-03-14 2010-12-02 바이오콘 리미티드 모노클로날 항체 및 그것의 방법
JP5882058B2 (ja) 2008-11-07 2016-03-09 ファブラス エルエルシー 組合せ抗体ライブラリー及びその使用
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2010121370A1 (en) * 2009-04-20 2010-10-28 University Health Network Prognostic gene expression signature for squamous cell carcinoma of the lung
ES2511051T3 (es) 2009-05-29 2014-10-22 Morphosys Ag Colección de anticuerpos sintéticos para tratar enfermedades
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US10016620B2 (en) * 2010-02-04 2018-07-10 Procept Biorobotics Incorporation Tissue sampling and cancer treatment apparatus
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
NZ631363A (en) 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
US9354228B2 (en) 2010-07-16 2016-05-31 Adimab, Llc Antibody libraries
CA2806076A1 (en) 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR20130110169A (ko) 2010-09-22 2013-10-08 암젠 인크 담체 면역글로뷸린 및 이것의 용도
SG189950A1 (en) 2010-11-19 2013-06-28 Morphosys Ag A collection and methods for its use
US20160272697A2 (en) * 2011-04-28 2016-09-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Neutralizing Antibodies to Nipah and Hendra Virus
CA3078215A1 (en) * 2011-04-28 2012-11-01 Department Of Veterans Affairs Identification of polynucleotides associated with a sample
CA3025762C (en) * 2011-05-04 2021-11-09 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
CN103596984B (zh) * 2011-06-15 2016-04-13 霍夫曼-拉罗奇有限公司 抗-人epo受体的抗体及使用方法
DK2739740T3 (da) 2011-08-05 2019-12-09 Regeneron Pharma Universelle, humaniserede letkæde-mus
DK2744931T3 (en) * 2011-08-18 2018-08-06 Affinity Biosciences Pty Ltd SOLUBLE POLYPEPTIDES
ES2707580T3 (es) 2011-09-23 2019-04-04 Oncomed Pharm Inc Agentes de unión a VEGF/DLL4 y usos de los mismos
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP2773665A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Antibodies and methods of treating cancer
AU2013208003B2 (en) 2012-01-09 2017-12-14 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US9150648B2 (en) * 2012-01-31 2015-10-06 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
WO2013131074A1 (en) * 2012-03-02 2013-09-06 Diogenix, Inc. Methods and reagents for evaluating autoimmune disease and determining antibody repertoire
WO2013134743A1 (en) 2012-03-08 2013-09-12 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CA2875543A1 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
WO2014071018A1 (en) * 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
WO2014074528A2 (en) * 2012-11-06 2014-05-15 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
WO2014085821A2 (en) * 2012-11-30 2014-06-05 The Regents Of The University Of California Fully human antibodies and fragments recognizing human c-met
LT2928921T (lt) 2012-12-05 2021-04-26 Novartis Ag Kompozicijos ir būdai, skirti antikūnams nukreipti į epo
WO2014116051A1 (ko) 2013-01-24 2014-07-31 스크립스코리아 항체연구원 단백질 조합 기반의 Fv 라이브러리 및 이의 제조 방법
US9896685B2 (en) 2013-04-25 2018-02-20 Sutro Biopharma, Inc. Use of LAMBDA-GAM protein in ribosomal display technology
US20160069897A1 (en) * 2013-04-25 2016-03-10 Suthro Biopharma, Inc. Selection of fab fragments using ribosomal display technology
RU2539752C2 (ru) * 2013-05-23 2015-01-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
PL3052192T3 (pl) * 2013-10-02 2021-04-06 Medimmune, Llc Przeciwciała neutralizujące przeciwko grypie A i ich zastosowania
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES2897765T3 (es) * 2014-03-14 2022-03-02 Hoffmann La Roche Procedimientos y composiciones para la secreción de polipéptidos heterólogos
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
CN106459213B (zh) 2014-04-03 2020-12-01 Igm生物科学股份有限公司 修饰的j链
EP3126397B1 (en) 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3160566B1 (en) * 2014-06-24 2020-03-11 Procept Biorobotics Corporation Tissue sampling and cancer treatment apparatus
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
EP3185897A4 (en) * 2014-08-29 2018-05-02 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and opri
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
JP6709215B2 (ja) 2014-10-27 2020-06-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 抗ｔｉｍ−３抗体
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
TW201625692A (zh) 2014-11-14 2016-07-16 諾華公司 抗體藥物結合物
EP3026060A1 (en) * 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
CN113388036A (zh) 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
EP3246434A1 (en) * 2015-01-13 2017-11-22 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
MX2017011600A (es) 2015-03-10 2018-06-13 Sorrento Therapeutics Inc Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3280443B1 (en) 2015-04-08 2022-08-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
AR104309A1 (es) 2015-04-17 2017-07-12 Bayer Pharma AG Construcciones de anticuerpos biespecíficos para cdh3 y cd3
KR20180015650A (ko) 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
US10787517B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
EP3297662A4 (en) 2015-05-18 2019-03-13 Agensys, Inc. ANTIBODIES BINDING TO AXL PROTEINS
LT3303384T (lt) 2015-06-01 2021-10-11 Medimmune, Llc Neutralizuojančios surišančios molekulės prieš gripą ir jų naudojimas
US20180155411A1 (en) * 2015-07-08 2018-06-07 The Board Of Trustees Of The Leland Stanford Junior University Heterotypic antibodies specific for human rotavirus
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
JP6967003B2 (ja) 2015-09-23 2021-11-17 メレオ バイオファーマ ５ インコーポレイテッド がんの処置のための方法および組成物
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
HUE050312T2 (hu) 2015-11-10 2020-11-30 Medimmune Llc ASCT2-RE specifikus kötõmolekulák és alkalmazásaik
EP3383914A4 (en) * 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017096182A1 (en) * 2015-12-03 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
CN105693821A (zh) * 2016-01-08 2016-06-22 中国药科大学 与人血管内皮生长因子受体-3(vegfr-3)蛋白特异性结合的多肽，其筛选方法，鉴定和用途
US11136407B2 (en) * 2016-01-08 2021-10-05 Aimm Therapeutics B.V. Therapeutic anti-CD9 antibody
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
JP7022067B2 (ja) * 2016-01-14 2022-02-17 メモリアル スローン ケタリング キャンサー センター Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
KR20180138205A (ko) 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
US11197937B2 (en) * 2016-04-15 2021-12-14 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
MX2018015757A (es) * 2016-06-14 2019-05-30 Merck Sharp & Dohme Anticuerpos antifactor de la coagulacion xi.
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Anti-pd-l1 antibodies
JP6987134B2 (ja) 2016-06-27 2021-12-22 ジュノー セラピューティクス インコーポレイテッド ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3510046A4 (en) * 2016-09-07 2020-05-06 The Regents of the University of California ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
CN118005799A (zh) * 2016-09-23 2024-05-10 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11667697B2 (en) 2016-10-19 2023-06-06 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
WO2018081754A1 (en) * 2016-10-29 2018-05-03 University Of Miami Anti-zika virus antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
ES3040144T3 (en) 2016-11-08 2025-10-28 Regeneron Pharma Antigen-binding proteins that antagonize leptin receptor
WO2018089628A1 (en) * 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
TW201832778A (zh) * 2016-11-10 2018-09-16 美商麥迪紐有限責任公司 對ａｓｃｔ２具有特異性的結合分子及其用途
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharmaceuticals, Inc. conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
SI3555132T1 (sl) * 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
CN108456250B (zh) * 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
CA3052779A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN110637031B (zh) * 2017-03-04 2024-04-16 湘潭腾华生物科技有限公司 程序性死亡蛋白1(pd-1)的重组抗体及其用途
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US10296425B2 (en) 2017-04-20 2019-05-21 Bank Of America Corporation Optimizing data processing across server clusters and data centers using checkpoint-based data replication
US11976121B2 (en) 2017-07-20 2024-05-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. CD123-binding chimeric antigen receptors
IL316357A (en) * 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CA3072816A1 (en) * 2017-08-18 2019-02-21 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
JP7291700B2 (ja) 2017-11-20 2023-06-15 ナントバイオ，インコーポレイテッド ｍＲＮＡディスプレイ抗体ライブラリー及び方法
US11034951B2 (en) 2017-11-20 2021-06-15 Nantbio, Inc. mRNA display antibody library and methods
KR20200100089A (ko) 2017-12-18 2020-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법
AU2018393074B2 (en) 2017-12-19 2025-10-23 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
CN111727203B (zh) 2017-12-19 2024-04-26 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
WO2019143884A1 (en) * 2018-01-19 2019-07-25 Vanderbilt University Conserved hiv antibody clonotypes and methods of use
WO2019157366A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
MX2020008684A (es) * 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
AU2019232631A1 (en) 2018-03-05 2020-09-24 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
TW201940515A (zh) * 2018-03-13 2019-10-16 英商塔斯克療法有限公司 抗-cd25抗體藥劑
WO2019195796A1 (en) 2018-04-06 2019-10-10 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
EP3553082A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
WO2020010235A1 (en) * 2018-07-05 2020-01-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Car t cells that target b-cell antigens
WO2020014143A1 (en) 2018-07-08 2020-01-16 Specifica Inc. Antibody libraries with maximized antibody developability characteristics
CN110713537B (zh) * 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3844266A1 (en) 2018-08-28 2021-07-07 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
CN109553680B (zh) * 2018-12-12 2021-06-01 广州市第八人民医院 一种单克隆抗体ZKns4B8及其应用
BR112021012569A2 (pt) * 2018-12-28 2021-09-14 Kyowa Kirin Co., Ltd. Anticorpo biespecífico de ligação ao tfr
JP7550770B2 (ja) * 2019-01-31 2024-09-13 ナントバイオ，インコーポレイテッド ｍＲＮＡディスプレイ抗体ライブラリー及び方法
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US12479908B2 (en) 2019-03-29 2025-11-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Antibodies against programmed cell death protein 1 (PD1) and uses thereof
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
GB2600274B (en) 2019-06-07 2024-11-27 Scribe Therapeutics Inc Engineered CasX systems
WO2020247883A2 (en) * 2019-06-07 2020-12-10 Scribe Therapeutics Inc. Deep mutational evolution of biomolecules
US12448462B2 (en) 2019-06-14 2025-10-21 Dana-Farber Cancer Institute, Inc. Antibodies against MUC1
AU2020300618A1 (en) * 2019-07-02 2022-01-27 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
EP3999532A2 (en) * 2019-07-16 2022-05-25 Sanofi Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
CN115003697A (zh) 2019-09-23 2022-09-02 特韦斯特生物科学公司 Crth2的变异核酸文库
US12173282B2 (en) * 2019-09-23 2024-12-24 Twist Bioscience, Inc. Antibodies that bind CD3 epsilon
BR112022007720A2 (pt) * 2019-10-24 2022-08-23 Prometheus Biosciences Inc Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos
WO2021202863A1 (en) * 2020-04-02 2021-10-07 Promab Biotechnologies, Inc. Human ror-1 antibody and anti-ror-1-car-t cells
JP2023523336A (ja) * 2020-04-27 2023-06-02 ツイスト バイオサイエンス コーポレーション コロナウイルス用の変異体核酸ライブラリー
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
AU2021277373A1 (en) * 2020-05-20 2023-01-05 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against SARS-CoV-2, generation and uses thereof
CN111748033B (zh) * 2020-05-27 2021-02-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒
IL298510A (en) 2020-06-12 2023-01-01 Nkarta Inc Genetically modified natural killer cells for cd70-directed cancer immunotherapy
TWI806088B (zh) * 2020-06-30 2023-06-21 大陸商和鉑醫藥（上海）有限責任公司 具有H2L2與HCAb結構的結合蛋白
AU2021324615A1 (en) * 2020-08-10 2023-03-09 Integral Molecular, Inc. Methods and compositions for making antibody libraries and antibodies isolated from the same
US20230391856A1 (en) * 2020-10-23 2023-12-07 Icahn School Of Medicine At Mount Sinai Sars-cov-2 antibodies and uses thereof
EP4256054A1 (en) 2020-12-03 2023-10-11 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
JP2023552762A (ja) * 2020-12-04 2023-12-19 エクイリウム，インコーポレイテッド Ｃｄ６ｈｉｇｈ細胞を選択的に標的化してｔｅｆｆ細胞の活性を低下する方法
CN117203228A (zh) * 2021-01-11 2023-12-08 阿迪马布有限责任公司 被工程化为优先进行链配对的变体ch1结构域和变体cl结构域以及包括所述变体ch1结构域和所述变体cl结构域的多特异性抗体
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
US20240327503A1 (en) * 2021-03-12 2024-10-03 Jimmy Dale GOLLIHAR Sars-cov-2 neutralizing antibodies and uses thereof
WO2022204316A2 (en) 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
WO2022266383A1 (en) * 2021-06-17 2022-12-22 Atreca, Inc. Anti-csp antibodies
JP2024526324A (ja) * 2021-07-12 2024-07-17 ンカルタ・インコーポレイテッド Ｂｃｍａ指向性細胞免疫療法の組成物および方法
CA3227150A1 (en) * 2021-07-23 2023-01-26 The Trustees Of Columbia University In The City Of New York Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use
JP2024527029A (ja) 2021-07-29 2024-07-19 セファロン リミティド ライアビリティ カンパニー 抗ｐａｃａｐ抗体の組成物及び方法
US11987641B2 (en) 2021-08-27 2024-05-21 Janssen Biotech, Inc. Anti-PSMA antibodies and uses thereof
AU2022335002A1 (en) * 2021-08-27 2024-04-11 Janssen Biotech, Inc. Anti-psma radioconjugates and uses thereof
CN118234750A (zh) * 2021-09-02 2024-06-21 纪念斯隆-凯特琳癌症中心 抗cd33抗体和其用途
AU2022340644A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting cd33 and uses thereof
WO2023034950A2 (en) * 2021-09-03 2023-03-09 Icahn School Of Medicine At Mount Sinai Anti-hcmv antibodies and antigen-binding fragments thereof
EP4466284A2 (en) * 2021-10-27 2024-11-27 Twist Bioscience Corporation Multispecific sars-cov-2 antibodies and methods of use
CN116333123A (zh) * 2021-12-22 2023-06-27 宝船生物医药科技(上海)有限公司 抗tnfr2抗体及其用途
EP4486382A2 (en) * 2022-03-04 2025-01-08 Coagulant Therapeutics Corporation Human antibodies against activated protein c and uses thereof
JP2025534161A (ja) * 2022-10-04 2025-10-14 ミンク セラピューティクス， インコーポレイテッド 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN116514998B (zh) * 2023-05-12 2023-09-15 再少年(北京)生物科技有限公司 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用
WO2025010375A2 (en) * 2023-07-03 2025-01-09 Uct Bioscience Co., Ltd. Anti-grp78 antibodies and their uses
WO2025015320A2 (en) * 2023-07-12 2025-01-16 Phenomic Ai Anti-cthrc1 t cell engagers and methods of using the same
TW202525855A (zh) * 2023-08-31 2025-07-01 美商艾克塞里克斯公司 Ｉｌｔ２結合劑及其用途
TW202515919A (zh) * 2023-09-01 2025-04-16 比利時商艾托斯比利時公司 抗ｔｒｅｍ２抗體及使用方法
WO2025081163A1 (en) * 2023-10-13 2025-04-17 GenCART, Inc. Compositions for the treatment of cancer
US20250255980A1 (en) * 2024-02-12 2025-08-14 Mbrace Therapeutics, Inc. Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78)
WO2025184137A1 (en) * 2024-02-27 2025-09-04 Adimab, Llc Influenza antibodies and methods of use thereof
CN117986346B (zh) * 2024-04-07 2024-07-26 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用
CN120399078A (zh) * 2025-05-08 2025-08-01 上海天泽云泰生物医药有限公司 靶向cd117的纳米抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
WO2005023993A2 (en) * 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
JP3127158B2 (ja) 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
AU6952498A (en) 1997-04-04 1998-10-30 Millenium Pharmaceuticals, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
DK1004669T3 (da) 1997-05-14 2007-08-27 Asahi Chemical Ind Hidtil ukendte differentieringsinhibitor
CA2337492A1 (en) 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20020102613A1 (en) 1999-05-18 2002-08-01 Hoogenboom Hendricus Renerus Jacobus Mattheus Novel Fab fragment libraries and methods for their use
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
WO2001097850A2 (en) 2000-06-23 2001-12-27 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
FR2816319B1 (fr) 2000-11-08 2004-09-03 Millegen Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030022240A1 (en) 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
EP1438402A2 (en) 2001-08-22 2004-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
CA2485732A1 (en) * 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
EP1848672A4 (en) 2005-02-01 2009-11-04 Morphosys Ag LIBRARIES AND METHOD FOR ISOLATING ANTIBODIES
US8716195B2 (en) 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
CA2630839C (en) 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
WO2007137616A1 (en) 2006-05-30 2007-12-06 Millegen Highly diversified antibody libraries
CL2007001623A1 (es) 2006-06-06 2008-01-18 Genentech Inc Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo.
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
CN101500605B (zh) 2006-08-07 2014-04-30 瑞泽恩制药公司 Dll4拮抗剂在治疗局部缺血性损伤中的用途
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US20080100597A1 (en) 2006-10-25 2008-05-01 Macrovision Corporation Method and apparatus to improve playability in overscan areas of a TV display
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JP2010517944A (ja) 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー Ｄｌｌ４シグナリング阻害薬およびその使用
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
JP5882058B2 (ja) 2008-11-07 2016-03-09 ファブラス エルエルシー 組合せ抗体ライブラリー及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
WO2005023993A2 (en) * 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
de Wildt, R. M. T. et al. "Antibody arrays for high-throughput screening of antibody-antigen interactions" Nature Biotechnology (2000) 18: 989-994 *
Rauchenberger, R. et al. "Human Combinatorial Fab Library Yielding Specific and Functional Antibodies against the Human Fibroblast Growth Factor Receptor 3" Journal of Biological Chemistry (2003) 278 (40): 38194-38205 *
Schofield, D. J. et al. "Application of phage display to high throughput antibody generation and characterization" Genome Biology (2007) 8: R254 *
Weaver-Feldhaus, J. M. et al. "Yeast mating for combinatorial Fab library generation and surface display" FEBS Letters (2004) 564: 24-34 *

Also Published As

Publication number Publication date
CA2742969A1 (en) 2010-05-14
CA2742968A1 (en) 2010-05-14
AU2009313551A1 (en) 2010-05-14
US20160194627A1 (en) 2016-07-07
US20200399359A1 (en) 2020-12-24
JP2016040246A (ja) 2016-03-24
WO2010054010A1 (en) 2010-05-14
US20120058906A1 (en) 2012-03-08
WO2010054007A1 (en) 2010-05-14
JP5882058B2 (ja) 2016-03-09
JP2016127850A (ja) 2016-07-14
US10774138B2 (en) 2020-09-15
AU2016204719A1 (en) 2016-07-28
EP2356146A1 (en) 2011-08-17
US9403904B2 (en) 2016-08-02
US20110318339A1 (en) 2011-12-29
US9221902B2 (en) 2015-12-29
JP2012508017A (ja) 2012-04-05
DK2356270T3 (da) 2016-12-12
EP2356270B1 (en) 2016-08-24
EP2356270A1 (en) 2011-08-17
AU2009313560A1 (en) 2010-05-14
AU2018201622A1 (en) 2018-03-29
AU2009313551B2 (en) 2015-12-17
JP2012508016A (ja) 2012-04-05
CA2742968C (en) 2020-06-09

Similar Documents

Publication Publication Date Title
US20200399359A1 (en) Combinatorial antibody libraries and uses thereof
AU2010315101B2 (en) Methods for affinity maturation-based antibody optimization
RU2732151C2 (ru) Библиотека зависимых от концентрации ионов связывающих молекул
US20040162413A1 (en) Methods of optimizing antibody variable region binding affinity
JP2018095645A (ja) ヒト化抗体
CN102164958A (zh) 使用通用抗体构架进行的兔抗体的人源化
WO2011035205A2 (en) Antibodies against candida, collections thereof and methods of use
US20090202986A1 (en) Methods of optimizing antibody variable region binding affinity
HK1150842A (en) Humanization of rabbit antibodies using a universal antibody framework

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired